INTRODUCTION
============

The methyl group is the simplest organic substituent, yet it is not only important for synthetic and medicinal chemistry ([@R1]) but also plays a central role in a wide range of biological processes, including DNA replication, protein modification, lipid biosynthesis, and various other metabolic pathways ([@R2]--[@R5]). Most biological methylation uses members of the *S*-adenosylmethionine (SAM) superfamily, commonly known as radical methyltransferases, in which SAM is selectively cleaved by its C─S bond under the reaction with various nucleophiles to generate stable *S*-adenosyl-[l]{.smallcaps}-homocysteine, leading to the methylation of complex molecules such as nucleic acids, proteins, and natural products in a S~N~2 manner ([Fig. 1A](#F1){ref-type="fig"}) ([@R6]--[@R7]). Inspiration by SAM, Baran and coworkers ([@R8]) developed an elegant methylating agent, zinc bis(phenylsulfonylmethanesulfinate), for the methylation of heteroarenes. Very recently, other methylating reagents such as 1,1-diborylmethane ([@R9]), α-iodosulfones ([@R10]), trimethylphosphate ([@R11]), 1-methoxy-2,2,6,6-tetramethylpiperidine (TEMPO-Me) ([@R12]), MeZnCl ([@R13]), Lewis base BH~3~/DMF ([@R14]), and \[Me~2~Cl\]\[Al(OTeF~5~)~4~\] ([@R15]) exhibit unique reactivity during the research of methylation. Despite these notable advances, the corresponding *d*~3~-methylation has not been well developed.

![Bioinspired invention of DMTT as a robust *d*~3~-methylating agent.\
(**A**) SAM methyl transferase mediated nucleophilic reactions. (**B**) Deuterium-labeled drugs and candidates. (**C**) Invention of *d*~3~-methylating reagent **DMTT**. Reaction conditions: (1) HCOOH (3.0 equiv, 88 wt % aqueous solution), CD~3~OD (10.0 equiv, \>99% D), H~2~SO~4~ (11.0 equiv, 98 wt %), reflux at 60°C for 4 hours to afford methyl-*d*~3~ formate; (2) dibenzothiophene (1.0 equiv), and above methyl-*d*~3~ formate, heat up to 60°C until the mixture became a clear solution. Photo credit: Yunfei Zhao, Nanjing University. EC~50~, half median effective concentration.](aba0946-F1){#F1}

Deuterium atoms can be used as tracer atoms to elucidate metabolic pathways in medicinal chemistry ([@R16]). Owing to the higher bond dissociation energy than the C─H bond, the incorporation of deuterium can impart marked improvements to drug candidates, related to absorption, distribution, and metabolism in organisms ([@R17]). Numerous efficient strategies of deuterium labeling techniques have been developed recently including direct H/D exchange ([@R18]--[@R19]), dehalogenative deuterium mediated by transition metal catalysis ([@R20]), bases ([@R21]--[@R22]), or radicals ([@R23]), and so on ([@R24]--[@R25]). A substantial number of deuterium-labeled drug candidates have been synthesized and submitted to clinical trials in the past few decades ([@R26]--[@R27]). Austedo with two OCD~3~ groups, as a treatment for symptoms of Huntington's disease, was finally approved by the U.S. Food and Drug Administration in 2017 as the first deuterated drug ([Fig. 1B](#F1){ref-type="fig"}) ([@R28]). In general, the *d*~3~-methylated group incorporation significantly affected the ADME (absorption, distribution, metabolism, and excretion)--related processes and attenuated metabolism of certain pharmacologically active compounds ([@R29]--[@R30]). From the viewpoint of synthetic chemistry, *d*~3~-methylation is the most ideal approach because it has the capability to directly introduce the D-labeled methyl group into structurally diverse molecules ([@R31]--[@R33]). Because of the presence of multiple nucleophilic sites in a complex molecule with subtle differences in the activation barriers, controlling the positional selectivity represents a key challenge. Traditionally, CD~3~I ([@R34]), (CD~3~)~2~SO~4~, and CD~3~OD have been widely used as deuterium methylating reagents, albeit with volatility, corrosion, toxicity, and carcinogenicity concerns ([@R35]--[@R36]). However, these highly reactive reagents usually lead to poor chemoselectivity and overmethylation. Reductive deuteriation of carboxylic acids ([@R37]), amides ([@R38]), and nitriles ([@R39]--[@R41]) provides protocols to incorporate d2-methyleneation. Nevertheless, the invention of a reagent to accomplish direct, scalable, and predictably selective *d*~3~-methylation under mild and environmentally friendly conditions is in high demand. Umemoto's reagent is a commercially available and widely used electrophilic trifluoromethylating agent ([@R42]). Bioinspired by the reactivity of SAM, together with the design principle of Umemoto's reagent, we report herein the invention of **DMTT** (5-(methyl-*d*~3~)-5*H*-dibenzo\[*b,d*\]thiophen-5-ium trifluoromethane sulfonate) ([@R43]), a *d*~3~-methylating agent using the dibenzo\[*b*,*d*\]thiophene framework to simplify the SAM structure, successfully blending high reactivity and selectivity with a safety profile that is particularly attractive for medicinal and pharmaceutical chemistry ([Fig. 1C](#F1){ref-type="fig"}). **DMTT** could be simply prepared from dibenzo\[*b*,*d*\]thiophene ([@R44]--[@R45]) and CD~3~OD in 91% yield on a large scale, and the compound is very stable when stored as a solid at ambient temperature. Significantly, the *d*~3~-methylation of **DMTT** with substrates proceeds in a biomimetic process, thus exhibiting excellent chemoselectivity under extremely mild conditions analogous to SAM chemistry in a living organism.

RESULTS
=======

Reaction condition optimization
-------------------------------

Trideuteromethylation of carboxylic acids is ubiquitously used in chemical research. Initially, we chose the carboxylic acid **1a** with a carboxyl and a *N*,*N*-dimethyl group to check the reactivity and selectivity of the **DMTT** agent ([Table 1](#T1){ref-type="table"}). Compared to the NMe~2~ substituent, the carboxylic group preferentially reacted with **DMTT**, forming the desired *d*~3~-methylation product **1b** in 90% isolated yield with deuterium retained completely in the presence of K~2~CO~3~ (entry 1). This *d*~3~-methylation process cannot proceed in the absence of base (entry 2). Screening of other bases did not provide higher yields (entries 3 and 4). When increasing the amount of **DMTT** to 1.5 equiv, the overmethylation product **1c** was formed in 20% yield (entry 5). Using CD~3~I as the deuterium source led to a different chemoselectivity. Using 1.0 equiv of CD~3~I proved to prefer quaternization of *N*,*N*-dimethyl group (entry 7), and a larger excess of CD~3~I generated a by-product **1d** with CD~3~/CH~3~ exchange (entry 7). In addition, the selection of (CD~3~)~2~SO~4~ provided the desired product **1b** in a much lower efficiency with 27% yield of by-product **1c** (entry 8). These results indicate that **DMTT** exhibited significantly different reactivity from CD~3~I and (CD~3~)~2~SO~4~ depending on the different sterically hindered leaving groups. In addition, other sulfur-based reagents were also examined. Dimethyl sulfoxide (DMSO)--*d*~6~ cannot promote the methylation-*d*~3~ process under our developed conditions (entry 9), while the reagent \[CD~3~Ph~2~S\]^+^OTf^−^ was proved to be less effective (entry 10).

###### Reaction development.

Reaction conditions: **1a** (0.2 mmol), **DMTT** (0.2 mmol), and base (0.4 mmol) in 2 ml of MeCN for 12 hours.

  ------------------------------------------------------------------------------
  **Entry**   **Variation from**\                            **1b/1c/1d/1e\***
              **the standard conditions**                    
  ----------- ---------------------------------------------- -------------------
  1           None                                           90 (99% D)\
                                                             †/0/0/0

  2           Without K~2~CO~3~                              0/0/0/0

  3           Using KOH                                      35 (99% D)/0/0/0

  4           Using DBU                                      50 (99% D)/16/0/0

  5           1.5 equiv of DMTT                              62 (99% D)/20/0/0

  6           CD~3~I (1.0 equiv.) instead of **DMTT**        2/0/0/8

  7^‡^        CD~3~I (5.0 equiv) instead of **DMTT**         7/0/43/10

  8           (CD~3~)~2~SO~4~ (1.0 equiv) instead of\        31/27/0/0
              **DMTT**                                       

  9           DMSO-*d*~6~ instead of **DMTT**                0/0/0/0

  10          \[CD~3~Ph~2~S\]^+^OTf^−^ instead of **DMTT**   64/0/0/0
  ------------------------------------------------------------------------------

\*^1^H NMR yields were presented using CH~2~Br~2~ as an internal standard.

†Isolated yield.

‡At 80°C.

On the basis of the tested conditions, 1.0 equiv of **DMTT** furnished the desired methyl-*d*~3~ esterification product in excellent yield and suppressed the generation of by-products. To further illustrate this selectivity, substrate **2a** with three nucleophilic sites was treated with **DMTT** under the above conditions ([Fig. 2](#F2){ref-type="fig"}). To our delight, compound **2a** reacted with **DMTT** also tends to form the esterification product **2b** in 76% yield. Again, treatment of CD~3~I and (CD~3~)~2~SO~4~ with **2a** under the same conditions showed poor selectivity. Therefore, **DMTT** should be used as a very important, predictable, and reliable reagent for trideuteromethylation.

![Investigations of compound 2a with DMTT agent.\
Reaction conditions: **2a** (0.2 mmol), DMTT (0.2 mmol), and base (0.4 mmol) in 2 ml of MeCN for 12 hours, ^1^H NMR yields were presented using CH~2~Br~2~ as an internal standard. rt, room temperature.](aba0946-F2){#F2}

![Pd-catalyzed C─H bond methylation-*d*~3~.\
Reaction conditions: substrates **34** (1.0 equiv), **DMTT** (3.0 to 1.2 equiv), Pd(OAc)~2~ (10 mol %), Cu(OAc)~2~ (1.2 equiv), and trifluoroacetate (TFA) (5.0 equiv) in 2 ml of dichloroethane (DCE) for 12 hours at 60°C. Isolated yields were presented. \*3.0 equivalents of **DMTT** were used. nd, not detected.](aba0946-F3){#F3}

DISCUSSION
==========

Application in late-stage modification and deuterated drug synthesis
--------------------------------------------------------------------

Following identification of the optimized *d*~3~-methylation with **DMTT** under developed mild conditions, various nucleophilic reagents bearing several possible reactive sites were examined ([Table 2](#T2){ref-type="table"}). Notably, the substrates with tertiary alcohol hydroxyl (**3a**) and amino (4a) groups were well tolerated. The reaction showed excellent selectivity for esterification (**3-4b**), in which alcohol elimination and *N*-methylation byproducts were not observed. When indole **5a** was used, the esterification product **5b** was obtained in 84% yield with the N─H bond preserved. α-Amino acid **6a** was also suitable for *d*~3~-methylation, resulting in 89% yield (**6b**). Numerous pharmaceuticals and natural products were also investigated, and various *d*~3~-methylated biomolecules were generated in good to excellent yields. As an important immune inhibitor, mycophenolic acid (**7a**) with multiple hydroxyl groups also reacted smoothly with sole selectivity. The carboxylic acid preferentially reacted with **DMTT** in the presence of hydroxyl groups and showed excellent selectivity (**8b-12b**) under practical mild conditions, avoiding the formation of intermolecular esterification and overmethylation using traditional CD~3~ reagents. When substrates had oxoimidazolidine and tetrahydrothiophene motifs, *d*~3~-methylation reacted exclusively at the carboxylic acid group (**13b**) in 65% yield with 99% D incorporation. Furthermore, oligopeptides were tested under standard conditions; **14b** and **15b** were obtained in 92 and 48% yields, respectively. Among the substrates, the reactions of **12a** and **14a** with **DMTT** were conducted on a gram scale without the loss of the yield or selectivity.

![Methyleneation of trifluoromethyl-substituted alkenes.\
Reaction conditions: substrates **36** (1.0 equiv), **DMTT** (2.0 equiv), and KHMDS (2.0 equiv) in 2 ml of tetrahydrofuran (THF) for 12 hours at room temperature. Isolated yields were presented.](aba0946-F4){#F4}

###### Substrate scope, late-stage modification, and deuterated drug synthesis.

Reaction conditions: substrates **a** (1.0 equiv), **DMTT** (1 to 2 equiv), and K~2~CO~3~ (2 to 4 equiv) in 2 ml of MeCN for 12 hours. Isolated yields were presented.

  --
  --

\*Reaction conditions: substrates **a** (1.0 equiv), **DMTT** (1.0 equiv), and KOH (2.0 equiv) in 2 ml of MeCN/H~2~O (v:v = 1/1) for 12 hours. Isolated yields were presented.

Next, the phenols, which have higher p*K*~a~ (where *K*~a~ is the acid dissociation constant) values than the corresponding carboxylic acids, were also investigated. The phenols containing hydroxyl (**16b**), indole N─H (**17b**), amine (**18b**), and amide (**19b**) substituents were well compatible, with excellent selectivity. The drug molecules **20-21a**, which have sensitive functional groups, including 2-azetidinone, aliphatic hydroxyl, and terminal alkynyl frameworks, could be late stage modified by **DMTT** at the phenolic hydroxyl selectively, and the products **20-21b** were generated on a gram scale without notable decreases in yields (95 to 96%) or selectivity. The structure of **21b** was also determined by x-ray crystallographic analysis. Notably, for the reaction of **DMTT** with (+)-ascorbic acid (**22a**), the two aliphatic hydroxyl groups were also tolerated, and two phenol ether groups were preferentially produced, generating product **22b** in 91% yield. Trideuteromethylation of pyridoxine (**23a**) formed the desired product **23b** in 83% yield, and side reactions such as pyridine *N*- and alcohol *O*-methylation were completely inhibited.

In addition, **DMTT** was compatible with many common biologically active functional groups. When 2-aminobenzenethiol (**24a**) is used, only S atom *d*~3~-methylation (**24b**) is observed. Cleland's reagent bearing two mercapto and two hydroxyl groups is used as a reducing or "deprotecting" agent for thiolated DNA ([@R46]), and it can undergo selective *d*~3~-methylation with **DMTT** at the mercapto group, leading to product **25b** in 76% yield. Using sulfonamides **26-28a** as substrates having amino and amide substituents, the reaction of **DMTT** shows excellent selectivity for the sulfonamide NH group, in which the N─H bond connected to the sulfone group has the lowest p*K*~a~ value. Last, spongouridine **28a** bearing three hydroxyl groups was also tested with **DMTT**, and the NH *d*~3~-methylated compound **29b** was obtained in 91% yield with excellent deuterium incorporation. Among the products, the molecular structures of **25-26b** were confirmed by x-ray analysis. In the presence of K~2~CO~3~, the methylation-*d*~3~ took place selectively on the carboxylic acids, phenols, and thiols with their NH~2~, NH, and alkyl-OH intact. The order of reactivity in increasing order is amines and alkyl-OH \< phenols \< carboxylic acids. In particular, *N*-methylated-*d*~3~ products were only observed when the NH connected with strong electron-withdrawing groups, such as *N*-sulfonyl or *N*,*N*-diacetyl groups.

H/D exchange at the C─H bonds of the precursors is a common method for the preparation of deuterium-labeled drug molecules ([@R31]). However, highly efficient and regioselective H/D exchange of a methyl group in a complex molecule remains challenging. With the **DMTT** reagent in hand, we can provide a reliable route to convert commercially available drugs to the corresponding *d*~3~-deuterated variants. For example, bifendatatum (**30a**), an antihepatitis drug, was hydrolyzed to form a carboxylic acid intermediate and then underwent *d*~3~-methylation with **DMTT**, producing the *d*~3~-bifendataum (**30b**) with high-level deuterium incorporation. Methoxsalen (**31a**) is a commercial drug used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to ultraviolet A light from lamps or sunlight. This substrate was demethylated in the presence of BBr~3~ and subsequently reacted with **DMTT** to generate *d*~3~-methoxsalen (**31b**) in 82% yield.

Application in Ni-catalyzed dimethylation-*d*~6~ of amines
----------------------------------------------------------

The direct methylation of a primary amine with methyl iodide ([@R47]) is usually not a feasible method for the preparation of secondary amines since overmethylation occurs to form quaternary ammonium salts. To further investigate the superiority of **DMTT**, dimethylation of primary amines was carried out smoothly in the presence of 10 mol% Ni(OAc)~2~·4H~2~O, leading to the *N*,*N*-dimethyl-*d*~3~ products in modern to good yields ([Table 3](#T3){ref-type="table"}). Compared with these developed approaches, **DMTT** showed excellent selectivity under mild conditions, and the overmethylation quaternary ammonium salts did not observe. The hydroxyl group is compatible in this system to deliver **33c** in 71% yield with 99% D incorporation. The aryl amines containing other dialkylamino groups, such as **33d** and **33e**, are also well tolerated to furnish the corresponding methylation-*d*~3~ products in 61 and 74% yield, respectively. When the substrate **32f** with active amino group was treated with **DMTT** under standard conditions, the **33f** was isolated in 46% yield with active amino intact. The reaction of alkyl amines with **DMTT** gave the corresponding methylation-*d*~3~ products in moderate yields. What is more, the functional molecules with amines groups (**33j** and **33k**) were also investigated. Using the developed method, the *d*~6~-aminophenazone **33l**, as important antipyretic analgesics, could be easily be synthesized from the available 4-aminoantipyrine **32l**. Last, the secondary amines such as diphenylaniline **32m** can also be easily *d*~3~-methylated in the presence of nickel catalyst affording the *N*-(methyl-*d*~3~)-*N*-phenylaniline **33m** in 74% yield.

###### Dimethylation-*d*~6~ of primary amines.

Reaction conditions: substrates **32** (1.0 equiv), **DMTT** (2 equiv), Ni(OAc)~2~·4H~2~O (10 mol%), and KF (2 equiv) in 2 ml of DCM/H~2~O (v:v = 20/1) for 12 hours. Isolated yields were presented.

  --
  --

\*1.0 equiv of **DMTT** was used.

Application in C─H bond activation and *d*~3~-methylation
---------------------------------------------------------

**DMTT** has also played an important role in the transition metal-catalyzed C─H bond activation ([Fig. 3](#F3){ref-type="fig"}) ([@R45]). Using pyridyl as directing group, the *ortho*-methylation-*d*~6~ was achieved in the presence of palladium catalyst, leading to the dimethylation-*d*~6~ product **35a** in 62% isolated yield with 99% D value. In the same condition, CD~3~I and (CD~3~)~2~SO~4~ failed to accelerate the methylation process. Increasing the steric hindrance of directing group and reducing the loading of **DMTT**, the *ortho*-monomethylation-*d*~3~ product **35b** was observed without any deuterium loss. Using acetylamino as directing group, monomethylation-*d*~3~ was detected in the presence of 1.2 equivalents of **DMTT** under standard condition, whereas only trace amount of *ortho*-bismethylation-*d*~3~ was observed. The drug molecules were also modified using the developed palladium catalyzed C─H bond methylation-*d*~3~. Phenacetin, which was used to treat fever, headache, and neuralgia, can be methylated-*d*~3~ smoothly to change pharmacological activity and avoid some side effects, leading the methyl-*d*~3~ phenacetin **35d** in 75% yield with 99% deuterium incorporation.

Application in d2-methyleneation of cyclopropanes
-------------------------------------------------

In addition to a *d*~3~-methylating agent, **DMTT** also showed the intrinsic reactivity of a sulfur ylide ([Fig. 4](#F4){ref-type="fig"}). For example, in the presence of strong base, **DMTT** underwent deprotonation to afford methylene intermediate, which captured by trifluoromethyl substituted alkenes **36** to furnish the deuterated cyclopropanes **37** under mild conditions. Various aryl substituted cyclopropanes were obtained in the yields of 50 to 72%, which provide a powerful evidence to prove the widely application value of **DMTT**.

CONCLUSION
==========

In conclusion, we have developed a new *d*~3~-methylating reagent, **DMTT**, and applied it in the many methylation processes, serving as a powerful approach to install deuterium in organic molecules and providing a new diagnostic tool in drug development. The advantage of this transformation is the simple experimental protocols, excellent selectivity, and high-level deuterium incorporation. We believe that this strategy will be used in drug modification in the pursuit of new deuterated therapeutics.

MATERIALS AND METHODS
=====================

General information
-------------------

Unless otherwise noted, all the reaction was performed under air atmosphere. All new compounds were fully characterized. ^1^H, ^13^C, and ^19^F nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 400 or 500 MHz spectrometer. ^1^H NMR spectra data were reported as δ values in parts per million relative to CDCl~3~ (δ = 7.26), CD~3~CN (δ = 1.94), CD~3~OD (δ = 3.31), or DMSO-*d*~6~ (δ = 2.50). ^13^C NMR spectra data were reported as δ values in parts per million relative to CDCl~3~ (δ = 77.00), CD~3~CN (δ = 118.30), CD~3~OD (δ = 49.15), or DMSO-*d*~6~ (δ = 39.52). Mass spectra were conducted at Micromass Q-Tof instrument electron spray ionization (ESI) and Agilent Technologies 5973N electron ionization (EI). Infrared spectra were recorded on a Fourier transform infrared spectrometer. All materials obtained from commercial suppliers were used without further purification.

General procedure for synthesis of trideuteromethyl reagent DMTT
----------------------------------------------------------------

According to our patent ([@R43]), to a 50-ml round flask was added formic acid (7.8 ml, 150 mmol, 3 equiv, 88 wt % aqueous solution), CD~3~OD (20.2 ml, 500 mmol, 10 equiv, *d* = 0.89 g/ml, 99% D). Then, sulfuric acid (8.8 ml, 165 mmol, 11 equiv, 98%) was added dropwise to the above solution with stirring. The reaction was heated at 60°C and stirred for 4 hours. The methyl-*d*~3~ formate containing a small amount of deuterated methanol was directly distilled at atmospheric pressure (33° to 38°C). The methyl-*d*~3~ formate was used without further purification.

A 50-ml round flask was charged with dibenzothiophene (9.2 g, 50 mmol, 1 equiv) and above distilled methyl-*d*~3~ formate. The mixture was stirred at 0°C, and Tf~2~O (20 ml) was added dropwise with stirring. Then, the reaction was heated up to 60°C. When the mixture became a clear solution, the reaction was poured into water (100 ml), extracted with CH~2~Cl~2~ $\left( 50~\text{ml} \times \mathfrak{g}3 \right)$, dried with MgSO~4~, and concentrated in vacuo. The obtained crude product was washed with Et~2~O $\left( 50~\text{ml} \times \mathfrak{g}3 \right)$ and dried under vacuum to afford the trideuteromethyl reagent DMTT (16.0 g, 91%, 99% D).

General procedure for synthesis of 3b-31b
-----------------------------------------

Carboxylic acid **a** (0.2 mmol, 1.0 equiv), **DMTT** (0.2 to 0.4 mmol, 1 to 2 equiv), K~2~CO~3~ (0.4 to 0.8 mmol, 2 to 4 equiv), and MeCN (2 ml) were added to a Schlenk tube. The reaction was stirred at room temperature for 12 hours. Then, the resulting mixture was concentrated in vacuo, and the residue was purified by column chromatography to afford the corresponding product b.

General procedure for synthesis of 33a-33 l
-------------------------------------------

Ni(acac)~2~ (0.02 mmol, 0.1 equiv), amines (0.2 mmol, 1.0 equiv), potassium fluoride (KF) (0.4 mmol, 2.0 equiv), **DMTT** (0.4 mmol, 2.0 equiv), and dichloromethane (DCM)/H~2~O (2 ml, v:v = 20:1) were added to a 25-ml Schlenk tube. The reaction was stirred at room temperature for 12 hours. Then, the resulting mixture was concentrated in vacuo, and the residue was purified by column chromatography to afford the corresponding products 33.

General procedure for synthesis of 35a-35d
------------------------------------------

Pd(OAc)~2~ (0.02 mmol, 0.1 equiv), **34** (0.2 mmol, 1.0 equiv), Cu(OAc)~2~ (0.24 mmol, 1.2 equiv), **DMTT** (0.24 to 0.6 mmol, 1.2 to 3.0 equiv), trifluoroacetate (TFA; 1.0 mmol, 5.0 equiv), and dichloroethane (DCE; 2 ml) were added to a 25-ml Schlenk tube. The reaction was stirred at 60°C for 12 hours. Then, the resulting mixture was concentrated in vacuo, and the residue was purified by column chromatography to afford the corresponding products **35**.

General procedure for synthesis of 37a-37d
------------------------------------------

**36** (0.2 mmol, 1.0 equiv), **DMTT** (0.4 mmol, 2.0 equiv), potassium bis(trimethylsilyl)amide (KHMDS) (0.4 mmol, 2.0 equiv), and tetrahydrofuran (THF; 2 ml) were added to a 25-ml Schlenk tube. The reaction was stirred at room temperature for 12 hours. Then, the resulting mixture was concentrated in vacuo, and the residue was purified by column chromatography to afford the corresponding products **37**.
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